RU2021100040A - Конденсированные бициклические соединения для лечения заболевания - Google Patents
Конденсированные бициклические соединения для лечения заболевания Download PDFInfo
- Publication number
- RU2021100040A RU2021100040A RU2021100040A RU2021100040A RU2021100040A RU 2021100040 A RU2021100040 A RU 2021100040A RU 2021100040 A RU2021100040 A RU 2021100040A RU 2021100040 A RU2021100040 A RU 2021100040A RU 2021100040 A RU2021100040 A RU 2021100040A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- alkyl
- group
- hydrogen
- heteroaryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 9
- 201000010099 disease Diseases 0.000 title claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 26
- 125000001072 heteroaryl group Chemical group 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 24
- 239000001257 hydrogen Substances 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 22
- 150000002431 hydrogen Chemical class 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 17
- 150000002367 halogens Chemical class 0.000 claims 17
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 16
- 125000002947 alkylene group Chemical group 0.000 claims 16
- -1 substituted Chemical class 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 125000003107 substituted aryl group Chemical group 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 102100038495 Bile acid receptor Human genes 0.000 claims 4
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 230000003143 atherosclerotic effect Effects 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000007870 cholestasis Effects 0.000 claims 1
- 231100000359 cholestasis Toxicity 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 208000006132 lipodystrophy Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095646P | 2014-12-22 | 2014-12-22 | |
| US62/095,646 | 2014-12-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017126128A Division RU2741387C2 (ru) | 2014-12-22 | 2015-12-21 | Конденсированные бициклические соединения для лечения заболевания |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2021100040A true RU2021100040A (ru) | 2021-02-02 |
| RU2021100040A3 RU2021100040A3 (enExample) | 2021-04-26 |
Family
ID=55300724
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021100040A RU2021100040A (ru) | 2014-12-22 | 2015-12-21 | Конденсированные бициклические соединения для лечения заболевания |
| RU2017126128A RU2741387C2 (ru) | 2014-12-22 | 2015-12-21 | Конденсированные бициклические соединения для лечения заболевания |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017126128A RU2741387C2 (ru) | 2014-12-22 | 2015-12-21 | Конденсированные бициклические соединения для лечения заболевания |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10167294B2 (enExample) |
| EP (1) | EP3237419B1 (enExample) |
| JP (2) | JP2017538773A (enExample) |
| KR (1) | KR20170117030A (enExample) |
| CN (1) | CN107438612A (enExample) |
| AU (2) | AU2015370588B2 (enExample) |
| BR (1) | BR112017013568A2 (enExample) |
| CA (1) | CA2971755A1 (enExample) |
| CL (1) | CL2017001661A1 (enExample) |
| CO (1) | CO2017007121A2 (enExample) |
| IL (1) | IL252849B (enExample) |
| MX (1) | MX369623B (enExample) |
| RU (2) | RU2021100040A (enExample) |
| SG (1) | SG11201704770YA (enExample) |
| WO (1) | WO2016103037A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201704770YA (en) * | 2014-12-22 | 2017-07-28 | Akarna Therapeutics Ltd | Fused bicyclic compounds for the treatment of disease |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| EP3274350A1 (en) * | 2015-03-26 | 2018-01-31 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| TW201808283A (zh) * | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| CN110128432B (zh) * | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| TW202114671A (zh) | 2019-07-23 | 2021-04-16 | 瑞士商諾華公司 | 包含fxr促效劑之治療 |
| AU2020319052A1 (en) | 2019-07-23 | 2022-01-27 | Novartis Ag | Combination treatment of liver diseases using FXR agonists |
| WO2021044287A1 (en) | 2019-09-03 | 2021-03-11 | Novartis Ag | Treatment of liver disease or disorder comprising actrii receptor antagonists |
| US20220347190A1 (en) | 2019-09-19 | 2022-11-03 | Novartis Ag | Treatment comprising fxr agonists |
| WO2021064575A1 (en) | 2019-09-30 | 2021-04-08 | Novartis Ag | Treatment comprising the use of fxr agonists |
| IL293894A (en) | 2019-12-20 | 2022-08-01 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
| KR20230124665A (ko) | 2020-12-22 | 2023-08-25 | 노파르티스 아게 | Cgas 관련 병태의 치료에 유용한 인돌 유도체 |
| CN116710450A (zh) | 2020-12-22 | 2023-09-05 | 诺华股份有限公司 | 用于治疗与cGAS相关的病症的吡咯并[3,2-b]吡啶衍生物 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004259009A1 (en) * | 2003-07-23 | 2005-02-03 | Exelixis, Inc. | Azepine derivatives as pharmaceutical agents |
| CA2633243C (en) * | 2005-12-15 | 2014-05-27 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| SG11201704770YA (en) * | 2014-12-22 | 2017-07-28 | Akarna Therapeutics Ltd | Fused bicyclic compounds for the treatment of disease |
-
2015
- 2015-12-21 SG SG11201704770YA patent/SG11201704770YA/en unknown
- 2015-12-21 RU RU2021100040A patent/RU2021100040A/ru not_active Application Discontinuation
- 2015-12-21 MX MX2017008456A patent/MX369623B/es active IP Right Grant
- 2015-12-21 KR KR1020177020205A patent/KR20170117030A/ko not_active Abandoned
- 2015-12-21 EP EP15831230.6A patent/EP3237419B1/en not_active Not-in-force
- 2015-12-21 AU AU2015370588A patent/AU2015370588B2/en not_active Ceased
- 2015-12-21 BR BR112017013568A patent/BR112017013568A2/pt not_active Application Discontinuation
- 2015-12-21 JP JP2017533540A patent/JP2017538773A/ja active Pending
- 2015-12-21 WO PCT/IB2015/002549 patent/WO2016103037A1/en not_active Ceased
- 2015-12-21 CA CA2971755A patent/CA2971755A1/en active Pending
- 2015-12-21 CN CN201580076617.4A patent/CN107438612A/zh active Pending
- 2015-12-21 RU RU2017126128A patent/RU2741387C2/ru active
-
2017
- 2017-06-12 IL IL252849A patent/IL252849B/en unknown
- 2017-06-22 US US15/630,189 patent/US10167294B2/en active Active
- 2017-06-22 CL CL2017001661A patent/CL2017001661A1/es unknown
- 2017-07-17 CO CONC2017/0007121A patent/CO2017007121A2/es unknown
-
2018
- 2018-12-31 US US16/237,017 patent/US10793577B2/en active Active
-
2020
- 2020-09-17 US US17/024,095 patent/US20210139490A1/en not_active Abandoned
- 2020-10-01 JP JP2020167254A patent/JP7089566B2/ja active Active
- 2020-10-13 AU AU2020256336A patent/AU2020256336A1/en not_active Abandoned
-
2023
- 2023-05-02 US US18/311,171 patent/US20240025914A1/en not_active Abandoned
-
2024
- 2024-10-24 US US18/925,911 patent/US20250206753A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2021100040A (ru) | Конденсированные бициклические соединения для лечения заболевания | |
| RU2017121588A (ru) | Конденсированные бициклические соединения для лечения заболевания | |
| JP2017538773A5 (enExample) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| RU2020110780A (ru) | Ингибитор fgfr и его медицинское применение | |
| JP2016503799A5 (enExample) | ||
| JP2015517574A5 (enExample) | ||
| JP2015520140A5 (enExample) | ||
| EA201591775A1 (ru) | Замещенные ароматические соединения и связанный с ними способ лечения фиброза | |
| RU2015100901A (ru) | Производные эфира гетероарилкарбоновой кислоты | |
| JP2016505614A5 (enExample) | ||
| RU2016143333A (ru) | Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение | |
| RU2017134013A (ru) | Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения | |
| JP2016506960A5 (enExample) | ||
| RU2015129546A (ru) | Нейроактивные 19-алкокси-17-замещенные стероиды, их пролекарства и способы лечения с их применением | |
| AR089019A1 (es) | Derivados modificados de 4-fenil-piridina | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2016506958A5 (enExample) | ||
| JP2017531688A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| JP2011513410A5 (enExample) | ||
| RU2010140627A (ru) | Производные пирролидина | |
| RU2019115059A (ru) | Модуляторы ror-гамма | |
| RU2018147263A (ru) | Фторированные 2-амино-4-(замещенные амино)фенилкарбаматные производные | |
| JP2017508794A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20220124 |